Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ascendis Pharma ASMEX:ASND1N 43 EV-to-EBIT is 39.67 as of Sep. 22, 2026, which is 38% below its 10-year median of 64.46. GuruFocus rates MEX:ASND1N with a GF Score™ of 43/100. The stock has 3 warning signs investors should review. Among 381 Biotechnology companies, Ascendis Pharma AS ranks worse than 79% on this metric.
Ascendis Pharma AS (MEX:ASND1N) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Ascendis Pharma AS's Enterprise Value for the quarter that ended in Jun. 2026 was MXN311,178 Mil.
Ascendis Pharma AS's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN6,559 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ascendis Pharma AS EV-to-EBIT Related Terms
Ascendis Pharma AS EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Ascendis Pharma AS's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:ASND1N vs JAZZ, BBIO, EXEL: EV-to-EBIT Comparison
For the Biotechnology subindustry, Ascendis Pharma AS's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ascendis Pharma AS EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ascendis Pharma AS's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Ascendis Pharma AS's EV-to-EBIT falls into.
Ascendis Pharma AS's current Enterprise Value is MXN260,222 Mil.
Ascendis Pharma AS's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN6,559 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ascendis Pharma AS (MEX:ASND1N) has a EV-to-EBIT of 39.67 as of Sep. 22, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Ascendis Pharma AS and its competitors. This is 38% below median its historical median of 64.46. According to the industry distribution chart, Ascendis Pharma AS ranks #301 out of 381 companies in the Biotechnology industry, placing it in the top 79%.
Is Ascendis Pharma AS's EV-to-EBIT too high?
Ascendis Pharma AS's current EV-to-EBIT of 39.67 is 38% below median its 10-year median of 64.46. The Biotechnology industry median EV-to-EBIT is 14.08. Ascendis Pharma AS's value of 39.67 is 181.7% above this industry median. Based on the distribution chart, Ascendis Pharma AS ranks #301 out of 381 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Ascendis Pharma AS has a GF Score™ of 43/100, reflecting its overall financial health beyond just this single metric.
How does Ascendis Pharma AS's EV-to-EBIT compare to JAZZ and BBIO?
According to the Biotechnology industry distribution chart, Ascendis Pharma AS ranks #301 out of 381 companies for EV-to-EBIT. This places Ascendis Pharma AS in the lower half of its industry. The industry median EV-to-EBIT is 14.08. Ascendis Pharma AS's value of 39.67 is 181.7% above this benchmark. While the company's 10-year median is 64.46 vs. the industry median of 14.08, Ascendis Pharma AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 14.08, based on 381 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ascendis Pharma AS's current EV-to-EBIT of 39.67 is 181.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Ascendis Pharma AS and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 14.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ascendis Pharma AS's current EV-to-EBIT is 39.67, which is 38% below median its own 10-year median of 64.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascendis Pharma AS stock overvalued right now?
Ascendis Pharma AS (MEX:ASND1N) has a current EV-to-EBIT of 39.67. The current EV-to-EBIT is 39.67, which is 38% below median its 10-year median of 64.46 and 181.7% above the Biotechnology industry median of 14.08. Ascendis Pharma AS's overall GF Score™ is 43/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Ascendis Pharma AS (MEX:ASND1N), the current EV-to-EBIT is 39.67 as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
43GF Score
Get the complete analysis for MEX:ASND1N
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:ASND1N has been successfully added to your 
